Since 1992, Omnicell has been creating innovative solutions to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for medication and supply management across the entire health care continuum—from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient’s home. Approximately 4,000 customers worldwide use Omnicell automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety. The recent acquisition of Aesynt adds distinct capabilities, particularly in central pharmacy and IV robotics, creating the broadest medication management product portfolio in the industry. The Omnicell SureMed solution provides innovative medication adherence packaging to help reduce costly hospital readmissions. In addition, these solutions enable approximately 7,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.
Mountain View, US
Size (employees)
2,444 (est)
Omnicell was founded in 1992 and is headquartered in Mountain View, US

Omnicell Office Locations

Omnicell has an office in Mountain View
Mountain View, US (HQ)
W Middlefield Rd

Omnicell Metrics

Omnicell Financial Metrics

Omnicell's revenue was reported to be $692.6 m in FY, 2016 which is a 43% increase from the previous period.

Revenue (FY, 2016)

$692.6 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

$313.8 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

$603 k

EBIT (FY, 2016)

$6.5 m

Market capitalization (22-May-2017)

$1.5 b

Closing share price (22-May-2017)


Cash (31-Dec-2016)

$54.5 m
Omnicell's current market capitalization is $1.5 b.
FY, 2013FY, 2014FY, 2015FY, 2016


$380.6 m$440.9 m$484.6 m$692.6 m

Revenue growth, %


Cost of goods sold

$177.2 m$207 m$236.6 m$378.8 m

Gross profit

$203.4 m$233.9 m$247.9 m$313.8 m

Gross profit Margin, %


Operating expense total

$168.1 m$184.3 m$199.3 m$307.3 m


$35.3 m$49.6 m$48.6 m$6.5 m

EBIT margin, %


Interest income

$270 k$2.4 m$8.4 m

Pre tax profit

$35 m$48.5 m$46.2 m

Income tax expense

$11.1 m$18 m$15.5 m($2.6 m)

Net Income

$24 m$30.5 m$30.8 m$603 k
FY, 2013FY, 2014FY, 2015FY, 2016


$104.5 m$125.9 m$82.2 m$54.5 m

Accounts Receivable


$31.5 m$46.6 m$69.3 m

Current Assets

$233.8 m$283.4 m$264.1 m$315.4 m


$35.3 m$36.2 m$32.3 m$42 m


$111.3 m$122.7 m$147.9 m$327.7 m

Total Assets

$492.5 m$560.2 m$578.7 m$935.1 m

Accounts Payable

$16.5 m$19.4 m$22.6 m$27.1 m

Current Liabilities

$92.4 m$112.3 m$124.6 m$180.9 m

Additional Paid-in Capital

$421.2 m$457.4 m$490.4 m$525.8 m

Retained Earnings

$38.5 m$69 m$99.8 m$100.4 m

Total Equity

$349 m$402.4 m$431.6 m

Financial Leverage

1.4 x1.4 x2.2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$24 m$30.5 m$30.8 m$603 k

Depreciation and Amortization

$18.4 m$20.3 m$25.6 m$58.4 m

Accounts Receivable

($3.6 m)($23 m)($18 m)$8 m


($5.4 m)$1.4 m($10 m)($3.4 m)

Accounts Payable

($1.8 m)$1.6 m($2.8 m)($5 m)

Cash From Operating Activities

$42.2 m$65.2 m$33.8 m$47.9 m

Purchases of PP&E

($12.3 m)($11.9 m)($7.5 m)($13.4 m)

Cash From Investing Activities

($20.5 m)($43.3 m)($45.6 m)($341.3 m)

Cash From Financing Activities

($206 k)($31.8 m)$265.7 m

Interest Paid

$122 k$61 k$76 k$5.3 m

Income Taxes Paid

$7.1 m
Y, 2016

Financial Leverage

2.2 x

Omnicell Market Value History

Omnicell Median Salaries

Source: 106 public H-1B filings from Omnicell

Omnicell Online Presence

Omnicell Company Life

You may also be interested in